CJ’s Exone eyeing bigger market share

CJ Cheil Jedang is striving to expand its share of the domestic hypertension combination drug market dominated by international drugmakers.

Exone, CJ’s new incrementally modified drug (IMD) containing valsartan and amlodipine adipate, is expected to challenge Exforge of Novartis and Twynsta of Boehringer Ingelheim based on its more cost-effective than competitors (70 percent cheaper than ...